QUANTICA
10.11.2022 11:46:41 CET | Business Wire | Press release
Last November at the international additive manufacturing exhibition Formnext, Quantica announced its T1 Pro, an R&D system that showcased the company’s multi-material, ultra-high viscosity jetting capabilities, known as NovoJet™. A year later, Quantica is back at the Frankfurt-based expo, this time introducing a new Desktop system– the NovoJet™ C-7.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005047/en/
The Berlin-based 3D printing start-up is pushing the boundaries of multi-material and high-performance material jetting, through the introduction of the NovoJet™ C-7. A printer suitable for research, feasibility studies, and small scale production of custom applications. It will be made available to research institutes and industry partners, looking to develop high-performance, multi-material 3D printing and other additive manufacturing applications.
NovoJet™ C-7 is an open printing platform, ideal for 2D and 3D application development using Quantica’s ultra-high viscosity jetting technology. It has been created for research institutes, R&D labs, and organizations looking to develop new additive manufacturing materials and workflows. Beyond feasibility testing and application development, the printer can also be used for customized and low-volume production, enabling a truly seamless transition from lab to production.
Key features of the NovoJet™ C-7 include:
- Material Experimentation: The system uses printheads capable of handling a wide range of fluids with viscosities exceeding 380mPa•s at jetting temperature, equating to approximately 4000mPa•s at ambient temperature. Along with experimentation with liquids with high particle loading.
- New Material Combinations: The system has the ability to control up to 7 material channels giving users access to new material combinations with better mechanical properties, color fidelity, and aesthetics.
- System Customization: The system offers customizable integrations for research and development needs.
The power of Quantica’s NovoJet™ printhead technology is its ability to print materials that are 15 times more viscous than legacy inkjet printheads. This opens up new possibilities for delivering high value end-part products with properties such as high toughness, temperature resistance, conductivity, biocompatibility, and flexibility manufactured in a single process.
Multiple industry partners, mainly within the dental, medical and electronics space, have started collaborations with Quantica to develop targeted solutions based on the novel capabilities.
“This new system unlocks enormous possibilities for the material deposition industries, giving material developers the ability to move past the limitations of low performance fluids and start developing new formulations with better properties of interest. In the end, we empower organizations to build products in new and exciting ways,” said Ramon Borrell, CTO of Quantica. “Quantica is already exploring several applications in the dental, healthcare, consumer goods, and electronics industries. We are excited to support these, and the many other, industries in breaking down current inkjet barriers and limitations.”
For more information about the NovoJet™ C-7, please visit https://quantica3d.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom